荆花胃康胶丸联合瑞巴派特治疗慢性萎缩性胃炎的临床研究  

Clinical study on Jinghua Weikang Capsules combined with rebamipide in treatment of chronic atrophic gastritis

作　　者：祁冉 郭虹[1] 苏秀丽[1] 冯庆 QI Ran;GUO Hong;SU Xiu-li;FENG Qing(Department of Gastroenterology,The First Affiliated Hospital of Henan University of Science and Technology,Luoyang 471003,China;Department of Gastroenterology,Liuzhou Workers’Hospital,Liuzhou 545000,China)

机构地区：[1]河南科技大学临床医学院河南科技大学第一附属医院消化内科,河南洛阳471003 [2]柳州市工人医院消化内科,广西柳州545000

出　　处：《现代药物与临床》2021年第5期952-956,共5页Drugs & Clinic

基　　金：广西壮族自治区卫生和计划生育委员会自筹经费科研课题(Z20180488)。

摘　　要：目的探讨荆花胃康胶丸联合瑞巴派特片治疗慢性萎缩性胃炎的临床疗效。方法选取2019年5月—2020年12月河南科技大学第一附属医院收治的92例慢性萎缩性胃炎患者为研究对象,按照随机数字表法将所有患者分为对照组和治疗组,每组各有46例。对照组患者口服瑞巴派特片,100 mg/次,3次/d。治疗组在对照组治疗的基础上口服荆花胃康胶丸,160 mg/次,3次/d。两组患者连续治疗8周。考察两组的临床疗效,比较两组患者生活质量、血清可溶性白细胞介素-2受体(SIL-2R)、前列腺素E2(PGE2)、白细胞介素-1β(IL-1β)、胃泌素-17(G-17)、胃蛋白酶原比值(PGR)、胃蛋白酶原Ⅰ(PGⅠ)水平。结果治疗后,治疗组的总有效率为91.30%,对照组的总有效率为76.81%,组间比较差异有统计学意义(P<0.05)。治疗后,两组的QHOQOL评分明显升高,差异有统计学意义(P<0.05);且治疗组QHOQOL评分比对照组高,差异有统计学意义(P<0.05)。治疗后,两组的SIL-2R、IL-1β水平明显降低,PGE2水平明显升高(P<0.05);治疗后,治疗组的SIL-2R、IL-1β水平低于对照组,PGE2水平高于对照组,差异有统计学意义(P<0.05)。治疗后,两组的G-17、PGR、PGⅠ水平明显升高,差异有统计学意义(P<0.05),且治疗组G-17、PGR、PGⅠ水平比对照组高,差异具有统计学意义(P<0.05)。结论荆花胃康胶丸联合瑞巴派特片可提高慢性萎缩性胃炎的疗效,减轻胃黏膜炎性损伤,调节胃肠激素分泌,安全性良好。Objective To investigate the clinical efficacy of Jinghua Weikang Capsules combined with Rebamipide Tablets in treatment of chronic atrophic gastritis. Methods Patients(92 cases) with chronic atrophic gastritis in The First Affiliated Hospital of Henan University of Science and Technology from May 2019 to December 2020 were randomly divided into control and treatment groups, and each group had 46 cases. Patients in the control group were po administered with Rebamipide Tablets, 100 mg/time, three times daily. Patients in the treatment group were po administered with Jinghua Weikang Capsules on the basis of the control group, 160 mg/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and quality of life, serum levels of SIL-2 R, PGE2, IL-1β, G-17, PGR, and PG Ⅰ in two groups were compared. Results After treatment, the total effective rate of the treatment group was 91.30%, the total effective rate of the control group was 76.81%, and the difference was statistically significant(P < 0.05). After treatment, the QHOQOL scores of two groups were significantly increased, and the difference was statistically significant(P < 0.05). The QHOQOL score of the treatment group was higher than that of the control group, and the difference was statistically significant(P < 0.05). After treatment, the levels of SIL-2 R and IL-1β in two groups were significantly decreased, but the level of PGE2 in two groups was significantly increased(P < 0.05). After treatment, the level of PGE2 in the treatment group was higher than that in the control group, while the levels of SIL-2 R and IL-1β in the treatment group were lower than that in the control group, and the difference was statistically significant(P < 0.05). After treatment, the levels of G-17, PGR, and PG Ⅰ in two groups were significantly increased(P < 0.05), and the levels of G-17, PGR, and PG Ⅰ in the treatment group were higher than those in the control group(P < 0.05). Conclusion Jinghua We

关 键 词：荆花胃康胶丸 瑞巴派特片 慢性萎缩性胃炎 生活质量 血清因子 

分 类 号：R975[医药卫生—药品]